24/7 Market News Snapshot 13 May, 2025 – Alzamend Neuro, Inc. Common Stock (NASDAQ:ALZN)

May 13, 2025

DENVER, Colo., 13 May, 2025 (www.247marketnews.com) – (NASDAQ:ALZN) are discussed in this article.
Alzamend Neuro, Inc. (NASDAQ:ALZN) is witnessing a notable surge in trading activity, currently standing at $6.54, reflecting a remarkable 27.03% increase from the previous closing price of $5.15. The trading session has been characterized by robust interest, with volumes reaching approximately 3.51 million shares. This bullish trend underscores significant market optimism, likely driven by recent advancements in the company’s innovative therapeutic options for neurodegenerative conditions.

In a key development, Alzamend has launched its first Phase II clinical trial for AL001, a next-generation lithium treatment designed to improve lithium delivery to the brain, thereby offering new avenues for patients suffering from Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The initiation of this trial highlights Alzamend’s dedication to creating safer, more effective treatment alternatives in the realm of neurological diseases.

Unlike traditional lithium therapies, AL001 is engineered to enhance brain absorption while minimizing systemic side effects. Initial studies conducted in animal models indicate that AL001 provides superior distribution of lithium in the brain, an essential component in optimizing therapeutic outcomes. The new study will concentrate on healthy subjects, establishing a vital foundation to assess the targeted effectiveness of AL001.

Stephan Jackman, CEO of Alzamend, emphasized the potential of AL001 to set a new standard in lithium treatment, advocating its emphasis on patient safety and the alleviation of traditional treatment burdens. The company is also progressing with an additional promising candidate, ALZN002, which targets the beta-amyloid deposits typical in Alzheimer’s patients, further marking its commitment to innovative solutions in neurological health.

As the company anticipates topline data by the end of the year, the momentum behind Alzamend showcases its ambition to substantially redefine treatment paradigms for mental health and neurodegenerative disorders.

Related news for (ALZN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.